- Home
- SRPT vs HSAI Comparison
SRPT vs HSAI Comparison
Compare SRPT & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRPT | HSAI |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRPT | HSAI |
|---|---|---|
| Price | $16.17 | $14.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 29 | 4 |
| Target Price | $25.85 | ★ $31.58 |
| AVG Volume (30 Days) | ★ 2.8M | 1.7M |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | N/A | $41.32 |
| P/E Ratio | ★ $5.56 | $61.18 |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $14.69 |
| 52 Week High | $25.32 | $30.85 |
Technical Indicators
Market Signals| Indicator | SRPT | HSAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 28.73 |
| Support Level | $15.10 | N/A |
| Resistance Level | $18.16 | $24.30 |
| Average True Range (ATR) | 0.79 | 0.73 |
| MACD | 0.18 | -0.27 |
| Stochastic Oscillator | 42.57 | 4.08 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
About HSAI Hesai Group each ADS represents one Class B ordinary share
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.